CytoSorbents Corporation (CTSO)

[Murph1953]

Some may find this interesting - informative and explanatory.

Published online 2015 Jul 15

Journal of Immunology Research

Sepsis: From Pathophysiology to Individualized Patient Care

"7. Treatment: What the Future Holds?"

7.1. Extracorporeal Removal of Mediators and Toxins

Extracorporeal clearance of the plasma, via hemofiltration and plasma pheresis, has received major interest over the last decades in sepsis research. As the results were contradictory, nowadays the focus of interest has turned towards new alternatives, such as the targeted removal of toxins and mediators via specific adsorption.

7.1.2. CytoSorb
CytoSorb is a hemadsorption device. It removes both proinflammatory and anti-inflammatory cytokines. The cartridge contains biocompatible, greatly porous polymer beads capable of absorbing molecules in the ~10–50?kDa range [85–87].

Cytokine overproduction is a common feature in many life-threatening conditions in addition to sepsis, such as trauma, major surgery in high risk patients, viral infections, acute respiratory distress syndrome (ARDS), serious burn injury, and acute pancreatitis, liver failure just to name a few. Several case reports have been published about the use of CytoSorb treatment over the last couple of years. These include ß-hemolytic streptococcus-induced necrotizing fasciitis [88], septic shock with multiorgan dysfunction [89], and rhabdomyolysis [90]. Elevated cytokine levels have been reported during donor conditioning for organ transplantation, which were associated with dysfunction of donor organs before and after transplantation [91, 92]. In a recent clinical trial it was found that, in addition to conventional treatment, attenuating the inflammatory response by cytokine absorption, graft survival can be prolonged [91].

from bib'

85. Taniguchi T. Cytokine adsorbing columns. Contributions to Nephrology. 2010;166:134–141. doi: 10.1159/000314863. [PubMed] [Cross Ref]

88. Hetz H., Berger R., Recknagel P., Steltzer H. Septic shock secondary to ß-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. International Journal of Artificial Organs. 2014;37(5):422–426. doi: 10.5301/ijao.5000315. [PubMed] [Cross Ref]

89. Basu R., Pathak S., Goyal J., Chaudhry R., Goel R. B., Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian Journal of Critical Care Medicine. 2014;18(12):822–824. doi: 10.4103/0972-5229.146321. [PMC free article] [PubMed] [Cross Ref]

90. Wiegele M., Krenn C. G. Cytosorb in a patient with legionella-pneumonia associated rhabdomyolysis. ASAIO Journal. 2015;61(3):e14–e16. doi: 10.1097/mat.0000000000000197. [PubMed] [Cross Ref]

91. Kellum J. A., Venkataraman R., Powner D., Elder M., Hergenroeder G., Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Critical Care Medicine. 2008;36(1):268–272. doi: 10.1097/01.ccm.0000291646.34815.bb. [PubMed] [Cross Ref]

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518174/